Published Studies Related to Xolegel (Ketoconazole Topical)
Efficacious and safe management of moderate to severe scalp seborrhoeic dermatitis using clobetasol propionate shampoo 0.05% combined with ketoconazole shampoo 2%: a randomized, controlled study. [2011.07]
BACKGROUND: Topical antifungals and corticosteroids are the mainstay of treatment for seborrhoeic dermatitis. The short-contact clobetasol propionate 0.05% shampoo (CP) is an efficacious and safe once-daily treatment for scalp psoriasis. OBJECTIVES: To evaluate the efficacy and safety of CP alone and combined with ketoconazole shampoo 2% (KC) in the treatment of moderate to severe scalp seborrhoeic dermatitis... CONCLUSIONS: The combination therapy of twice-weekly CP alternating with twice-weekly KC provided significantly greater efficacy than KC alone and a sustained effect in the treatment of moderate to severe scalp seborrhoeic dermatitis. (c) 2011 The Authors. BJD (c) 2011 British Association of Dermatologists 2011.
Synergistic effects of tetrandrine on the antifungal activity of topical
ketoconazole cream in the treatment of dermatophytoses: a clinical trial. 
dermatophytoses... CONCLUSION: TET synergistically enhanced the clinical efficacy of topical KZC
Comparative evaluation of ketoconazole tablet and topical ketoconazole 2% in orabase in treatment of Candida-infected denture stomatitis. [2010.03.01]
CONCLUSION: Topical ketoconazole 2% in orabase can be useful in managing denture stomatitis. This topical medication has fewer side effects, whereas systemic administration of ketoconazole tablet is associated with some complications. CLINICAL SIGNIFICANCE: The application of topical ketoconazole 2% in orabase ointment can be considered in the treatment of denture stomatitis and has comparable efficacy with the ketoconazole tablet.
Comparative efficacy and tolerability of Ketomousse (ketoconazole foam 1%) and ketoconazole cream 2% in the treatment of pityriasis versicolor: results of a prospective, multicentre, randomised study. [2008.11]
Ketomousse (K), a new thermophobic formulation (ketoconazole 1%), has proven its efficacy in the treatment of dandruff, caused by the same agent as pityriasis versicolor (PV). The objective of this study was to compare the efficacy and tolerability of K thermophobic foam vs...
A novel foam formulation of ketoconazole 2% for the treatment of seborrheic dermatitis on multiple body regions. [2007.10]
BACKGROUND: A novel topical foam formulation of ketoconazole has been developed for use on the scalp, body, and face. OBJECTIVE: To evaluate the efficacy and safety of twice-daily treatment with ketoconazole 2% foam for seborrheic dermatitis on the scalp, body, and face... CONCLUSION: Ketoconazole foam 2% is a safe, effective, and versatile formulation for use on the scalp, body, and face for the treatment of seborrheic dermatitis in patients aged 12 years or older.
Clinical Trials Related to Xolegel (Ketoconazole Topical)
Ketoconazole Foam 2% for the Treatment of Versicolor [Recruiting]
1. To assess the efficacy of ketoconazole 2% foam for the treatment of tinea versicolor
2. To assess the safety of ketoconazole 2% foam for the treatment of tinea versicolor
based on the occurrence of adverse events.
3. To assess treatment satisfaction as rated by patients
This will be a mono-centered, single arm, open-label pilot study. Ten adult patients age 19
and older with a clinical diagnosis of tinea versicolor, as well as a positive KOH using
calcofluor, will be enrolled at the University of Alabama at Birmingham. There will be 4
scheduled visits (baseline, week 1, week 2, and week 4). A target area will be identified
and mycological and clinical assessments will be performed at this site as well as a global
assessment of each subject. Ketoconazole 2% foam will be applied to all affected areas for 2
weeks with a follow-up visit at week 4. Skin scraping using a disposable #15 blade for
calcofluor/KOH assessment and photographs of target lesions will be performed at baseline,
week 1, week 2, and week 4. Photographs will be taken at baseline and at week 4 (only if KOH
is positive). Body surface area estimation of disease will also be performed at each visit.
Evaluation of scale, hyperpigmentation/erythema, and hypopigmentation using a 4 point scale
(0 = none, 1 = mild, 2 = moderate, 3 = severe) of the target area will be performed at
baseline, week 1, week 2, and week 4. A global assessment will be conducted at each visit
using the same 4 point scale. Patient questionnaires will be administered at baseline and
week 2 to assess symptoms and satisfaction with study medication.
Ketoconazole and Dexamethasone in Prostate Cancer [Recruiting]
This is an open label, phase II, single center trial of ketoconazole/dexamethasone to
determine if the administration of ketoconazole/dexamethasone, after disease progression
with ketoconazole/hydrocortisone slows or reverses disease progression in men with
progressive prostate cancer.
Seborrheic Dermatitis: Ketoconazole 2% Foam Versus Ketoconazole 2% Shampoo [Recruiting]
The aims of this study are to compare the effectiveness of antifungal foam versus antifungal
shampoo and determine patient compliance and satisfaction with both vehicles among African
American females with dandruff practicing less than once weekly hair washing.
Use of Low Dose Ketoconazole in Prostate Cancer That Does Not Respond to Hormone Therapy and Prior Chemotherapy [Recruiting]
The purpose of this study is to test the safety of ketoconazole and how well it works after
chemotherapy has been used. Ketoconazole at lower doses has been used for fungal infections
however has not yet been approved by the Food and Drug Administration for use in prostate
cancer. Ketoconazole has been used for many years at high doses for prostate cancer, and
this study will be to look at use of lower dose ketoconazole after someone has received
chemotherapy. Ketoconazole works by halting the production of steroids in your body,
including testosterone, and is thought to work directly on prostate cancer cells in
published lab studies.
A Study to Assess the Effect of Ketoconazole on the Metabolism of ABT-263 (Navitoclax). [Recruiting]
This is a single dose, open-label, single or multiple center study to determine the
interaction of ketoconazole with ABT-263 in approximately 12 subjects with cancer.